Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Agomelatine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    38 result(s) found for: Agomelatine. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2006-005674-47 Sponsor Protocol Number: CL3-20098-050 Start Date*: 2007-10-26
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Long-term efficacy and safety of agomelatine in non-depressed out-patients with Generalized Anxiety Disorder.A 26-week randomised double-blind placebo-controlled parallel group study following an ...
    Medical condition: Generalised anxiety disorder
    Disease: Version SOC Term Classification Code Term Level
    10.0 10018075 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FI (Completed) SE (Completed) EE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-003313-42 Sponsor Protocol Number: AGO-TEA Start Date*: 2012-03-29
    Sponsor Name:Hospital General Universitario de Alicante
    Full Title: Efficacy of agomelatine on sleep disturbance in Autism Spectrum Disorder (ASD)
    Medical condition: The treatment of sleep disorders in patients with autism spectrum disorders (ASD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003421-17 Sponsor Protocol Number: CL3-20098-051 Start Date*: 2009-02-18
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment at 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, dou...
    Medical condition: Generalized Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    11.0 10018075 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001666-15 Sponsor Protocol Number: CL3-20098-087 Start Date*: 2013-06-11
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of 2 doses of agomelatine (10 mg/day or 25 mg/day) versus placebo given orally for 12 weeks in non depressed out-patients with Generalized Anxiety Disorder. A 12-week randomise...
    Medical condition: Generalized Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004873 10018105 Generalized anxiety disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-002362-21 Sponsor Protocol Number: 14178A Start Date*: 2011-11-15
    Sponsor Name:H. Lundbeck A/S
    Full Title: A randomised, double-blind, parallel-group, active-controlled, flexible dose study evaluating the effects of Lu AA21004 versus agomelatine in adult patients suffering from major depressive disorder...
    Medical condition: -Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) EE (Completed) CZ (Completed) LT (Completed) DE (Completed) ES (Completed) PL (Completed) AT (Completed) BG (Completed) GB (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003699-37 Sponsor Protocol Number: CL3-20098-089 Start Date*: 2013-01-17
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of agomelatine (25mg/day with blinded potential adjustment to 50mg/day) versus escitalopram (10mg/day with blinded potential adjustment to 20mg/day) given orally for 12 weeks in...
    Medical condition: Generalized Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10018075 Generalised anxiety disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) HU (Completed) PL (Completed) FI (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2010-019423-61 Sponsor Protocol Number: GENRAS Start Date*: 2010-10-28
    Sponsor Name:Medizinische Universität Wien,Univ.Klinik f.Psychiatrie und Psychotherapie
    Full Title: GENRAS (GENetics of Response to Agomelatine vs. EScitalopram)
    Medical condition: depressive disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003404-12 Sponsor Protocol Number: CL2-20098-075 Start Date*: 2013-02-12
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Pharmacokinetics and safety of agomelatine in children (from 7 to less than 12 years) and adolescents (from 12 to less than 18 years) with Depressive or Anxiety Disorder. An open-labelled, multice...
    Medical condition: Depressive or Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    17.0 10037175 - Psychiatric disorders 10057666 Anxiety disorder PT
    17.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) HU (Completed) EE (Completed) RO (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-004881-17 Sponsor Protocol Number: CL3-20098-047 Start Date*: 2006-05-01
    Sponsor Name:Institut de Recherches Internationales Servier [...]
    1. Institut de Recherches Internationales Servier
    2. Laboratorios Servier S.L. (For Spain only)
    Full Title: Efficacy and safety of agomelatine (25 mg/day with potential adjustment at 50 mg/day) given orally compared to placebo, in addition to a mood stabilizer in Bipolar I patients with a current major d...
    Medical condition: Major depressive episode in the framework of bipolar disorder
    Disease: Version SOC Term Classification Code Term Level
    7.0 10004939 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) NL (Completed) ES (Completed) FI (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023576-10 Sponsor Protocol Number: CL3-20098-083 Start Date*: 2011-06-06
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Early effect of agomelatine on general interest in outpatients with Major Depressive Disorder. A 12-week, randomized, double-blind, multicentre study with parallel groups: agomelatine (25mg/day giv...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: View results
    EudraCT Number: 2004-002577-23 Sponsor Protocol Number: CL2-20098-040 Start Date*: 2004-12-08
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of Agomelatine (25 mg with potential adjustment at 50 mg) given orally once a day for 12 weeks in out-patients with Generalised Anxiety Disorder. A randomised flexible dose doub...
    Medical condition: Generalised Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    3.3 10018075 P.T.
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2009-013789-17 Sponsor Protocol Number: CL3-20098-071 Start Date*: 2010-03-11
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment to 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, dou...
    Medical condition: Generalized anxiety disorder
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10018105 Generalized anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2009-011238-84 Sponsor Protocol Number: CL3-20098-069 Start Date*: 2009-09-21
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of 3 dose regimens of agomelatine (10, 25, 25-50 mg) versus placebo given once a day for 6 weeks in out-patients suffering from moderate to severe Major Depressive Disorder. A 6...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    11.1 10057840 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed) BG (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2008-004642-92 Sponsor Protocol Number: CL3-20098-062 Start Date*: 2009-04-01
    Sponsor Name:Laboratorios Servier S.L.
    Full Title: Evaluación de la eficacia y el beneficio clínico de agomelatina (25 a 50 mg/día) durante un período de tratamiento de 6 meses en pacientes con Trastorno Depresivo Mayor.Estudio aleatorizado, doble ...
    Medical condition: Trastorno Depresivo Mayor//Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    11.0 10057840 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) PT (Completed) HU (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005320-17 Sponsor Protocol Number: CL3-20098-060 Start Date*: 2012-06-13
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Effects of agomelatine versus escitalopram on emotional experiences in outpatients suffering from Major Depressive Disorder. An exploratory, randomised, double-blind, international, multicentre stu...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-003981-13 Sponsor Protocol Number: CL3-20098-041 Start Date*: 2004-12-16
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: A study to determine the maintenance of efficacy of agomelatine (25 mg to 50 mg) to prevent relapse in out-patients with Major Depressive Disorder. A 8 to 10 weeks open period treatment with agome...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    3.3 10025453 P.T.
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002181-23 Sponsor Protocol Number: CL3-20098-076 Start Date*: 2015-12-14
    Sponsor Name:Institut de Recherche International Servier
    Full Title: Efficacy and safety of 2 doses of agomelatine (10mg, 25mg) given orally in children (from 7 to less than 12 years) and adolescents (from 12 to less than 18 years) with moderate to severe Major Depr...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) HU (Completed) DE (Ongoing) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-002388-95 Sponsor Protocol Number: CL3-20098-048 Start Date*: 2005-11-02
    Sponsor Name:Institut de Recherches Internationales Servier [...]
    1. Institut de Recherches Internationales Servier
    2. Laboratorios Servier S.L. (For Spain only)
    Full Title: Efficacy of agomelatine (25 to 50 mg/day) given orally on quality of remission in elderly depressed patients, after a 12-week treatment period.A randomised, double-blind, flexible-dose internationa...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    3.3 10025453 P.T.
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DK (Completed) ES (Completed) BE (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-024191-25 Sponsor Protocol Number: CL3-20098-080 Start Date*: 2012-03-30
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Effects of agomelatine (25 to 50 mg/day) on circadian rhythms in patients with Major Depressive Disorder. An exploratory 6-week open, flexible dose, international multicentre, non comparative study.
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    17.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-014045-92 Sponsor Protocol Number: CL2-90098-009 Start Date*: 2010-01-12
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of 3 doses (0.25, 0.5 and 1mg/day) of agomelatine sublingual administration over an 8-week treatment period, in out-patients with Major Depressive Disorder. An 8-week randomis...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) FR (Completed) CZ (Completed) SE (Completed) EE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 23 09:04:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA